Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study

European Journal of Epidemiology

Volumn 31, Issue 1, 2016, Pages 67-72

  Ghaderi, Sara ^a   Gunnes, Nina ^a   Bakken, Inger Johanne ^a   Magnus, Per ^a   Trogstad, Lill ^a   Håberg, Siri Eldevik ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Guillain Barr syndrome; Influenza; Norway; Pandemrix ; Registry; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; NORWAY; PANDEMIC INFLUENZA; RISK; VACCINATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPLICATION; GUILLAIN-BARRE SYNDROME; HEALTH SURVEY; HOSPITALIZATION; INCIDENCE; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; PANDEMIC; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; UTILIZATION;

FEMALE; GUILLAIN-BARRE SYNDROME; HOSPITALIZATION; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NORWAY; PANDEMICS; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REGRESSION ANALYSIS; RISK; VACCINATION;

EID: 84958743470     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-015-0047-0     Document Type: Article

References (23)

1. Guillain-Barré Syndrome Fact Sheet. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/gbs/detail_gbs.htm. Accessed 25 October 2014.
2. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7(10):939–50. doi:10.1016/s1474-4422(08)70215-1.
3. Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barre Syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case–centered analysis in the vaccine safety Datalink, 2009–2011. PLoS ONE. 2013;8(6):e67185. doi:10.1371/journal.pone.0067185.
4. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105–23.
5. Salmon DA, Proschan M, Forshee R, et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381(9876):1461–8. doi:10.1016/S0140-6736(12)62189-8.
6. Prestel J, Volkers P, Mentzer D, Lehmann HC, Hartung HP, Keller-Stanislawski B. Risk of Guillain-Barre syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. Pharmacoepidemiol Drug Saf. 2014. doi:10.1002/pds.3638.
7. Souayah N, Yacoub HA, Khan HM, et al. Guillain-Barre syndrome after H1N1 vaccination in the United States: a report using the CDC/FDA vaccine adverse event reporting system (2009). Neuroepidemiology. 2012;38(4):227–32. doi:10.1159/000336113.
8. Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. Vaccine. 2011;29(45):7878–82. doi:10.1016/j.vaccine.2011.08.069.
9. Verity C, Stellitano L, Winstone AM, Stowe J, Andrews N, Miller E. Pandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barre syndrome. Arch Dis Child. 2014;99(6):532–8. doi:10.1136/archdischild-2013-304475.
10. Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barre syndrome following influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013;31(40):4448–58. doi:10.1016/j.vaccine.2013.06.032.
11. Romio S, Weibel D, Dieleman JP, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PLoS ONE. 2014;9(1):e82222. doi:10.1371/journal.pone.0082222.
12. Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barre syndrome after exposure to influenza virus. Lancet Infect Dis. 2010;10(9):643–51. doi:10.1016/S1473-3099(10)70140-7.
13. Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis. 2014;58(8):1149–55. doi:10.1093/cid/ciu005.
14. Dieleman J, Romio S, Johansen K, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case–control study in Europe. BMJ. 2011;343:d3908. doi:10.1136/bmj.d3908.
15. Norsk pasientregister (NPR). The Norwegian Directorate of Health, Oslo, Norway. www.helsedirektoratet.no/npr. Accessed 02 October 2014.
16. Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B. The Norwegian immunisation register–SYSVAK. Euro Surveill. 2012;17(16). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20147
17. Norwegian surveillance system for communicable diseases (MSIS). The Norwegian Instiute of Public Health, Oslo, Norway. http://www.fhi.no/eway/default.aspx?pid=240&trg=Main_6664&Main_6664=6898:0:25,7846:1:0:0:::0:0. Accessed 02 October 2014.
18. Haberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med. 2013;368(4):333–40. doi:10.1056/NEJMoa1207210.
19. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768–97. doi:10.1002/sim.2302.
20. Crawford NW, Cheng A, Andrews N, et al. Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza a immunisation in Victoria: a self-controlled case series. Med J Aust. 2012;197(10):574–8.
21. De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. JAMA. 2012;308(2):175–81. doi:10.1001/jama.2012.7342.
22. Vellozzi C, Iqbal S, Stewart B, Tokars J, DeStefano F. Cumulative risk of Guillain-Barre syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic. Am J Public Health. 2014;104(4):696–701. doi:10.2105/AJPH.2013.301651.
23. Blasio BF, Iversen BG, Tomba GS. Effect of vaccines and antivirals during the major 2009 A(H1N1) pandemic wave in Norway–and the influence of vaccination timing. PLoS ONE. 2012;7(1):e30018. doi:10.1371/journal.pone.0030018.